SunRegen Healthcare AG is a biopharmaceutical company dedicated to developing drugs that address the unmet medical needs of patients with neurodegenerative diseases. Our focus encompasses innovative treatments for neurological, neuromuscular, and ophthalmic conditions. Our first product candidates target primary optic atrophy, and we are also exploring their potential use in serious neurological and neuromuscular diseases such as ALS, Huntington's, Alzheimer's, and Parkinson's disease.

Our team consists of passionate and innovative founders and experts with extensive experience in drug development and clinical research, as well as management expertise in international technology enterprises. We are determined to bring life-changing treatments to patients, and we believe in the significance of our mission. At SunRegen Healthcare AG, we aim to provide solutions for these significant health problems by developing drug candidates with strong neuroprotective effects, promoting neurite outgrowth, and indicating neuroregenerative effects.

We anticipate a favorable safety and tolerability profile for our products, along with good uptake by the brain. We welcome partnerships and collaboration with professional CROs/CMOs, academic institutions, and service organizations related to pharmaceutical development. Investors have shown confidence in our vision and have supported us in our journey.

If you are interested in investing in SunRegen Healthcare AG or joining our team, please reach out to us. Together, we can make a difference in the lives of patients suffering from neurodegenerative diseases. Contact us to learn more